VALA SCIENCES, INC.
High-throughput cell imaging platform with AI-powered image analysis for drug discovery
- Sector
- Medtech
- Headquarters
- San Diego, CA
- Latest Form D
- $1.3M, Sep 2015
- Total capital
- $17.4M
- Federal grants
- $16.2M
- 28 awards · 2015–2025
- Rank in peer group#6 of 112
- Private capital raised
- $1.3M
- 1 Form D · last Sep 2015
- 133 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 10 pending · first 2018
- Rank in peer group#18 of 112
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo & HIV ARTs)$1.1M
- Federal grantHealth and Human S · Phase II · An assay suite featuring hiPSC-derived neurons and support cells, to test toxicants and industrial chemicals for developmental neurotoxic effects$756K
- Federal grantHealth and Human S · Phase II · Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo & HIV ARTs)$1.1M
- Federal grantHealth and Human S · Phase II · Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes$153K
- Federal grantHealth and Human S · Phase II · Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes$14K
- Federal grantHealth and Human S · Phase II · Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes$174K
- Federal grantHealth and Human S · Phase II · Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes$920K
- Private capital raisedForm D · SEC · 1st filing$1.3M
Show 20 earlier federal awards
- Federal grantHealth and Human S · Phase II · Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes$10K
- Federal grantHealth and Human S · Phase II · An assay suite featuring hiPSC-derived neurons and support cells, to test toxicants and industrial chemicals for developmental neurotoxic effects$1.2M
- Federal grantHealth and Human S · Phase II · Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes$17K
- Federal grantHealth and Human S · Phase II · Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes$120K
- Federal grantHealth and Human S · Phase I · The Pain in a Dish Assay (PIDA): a high throughput system featuring human stem cell-derived nociceptors and dorsal horn neurons to test compounds for analgesic activity$350K
- Federal grantHealth and Human S · Phase II · Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo & HIV ARTs)$566K
- Federal grantHealth and Human S · Phase I · Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo and HIV ARTs)$566K
- Federal grantHealth and Human S · Phase II · Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes$1.1M
- Federal grantHealth and Human S · Phase II · The hCNS-HIV/ARV assay system, a platform utilizing human iPSC-neurons/-microglia/-astrocytes to test HIV/AIDS therapeutics for neurotoxicity related to HIV-associated cognitive disroder (HAND)$941K
- Federal grantHealth and Human S · Phase II · Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes$300K
- Federal grantHealth and Human S · Phase II · The hCNS-HIV/ARV assay system, a platform utilizing human iPSC-neurons/-microglia/-astrocytes to test HIV/AIDS therapeutics for neurotoxicity related to HIV-associated cognitive disroder (HAND)$1.9M
- Federal grantHealth and Human S · Phase II · Assay of chemicals for Parkinson's toxicity in human iPSC-derived neurons$742K
- Federal grantHealth and Human S · Phase I · The Alzheimer's Therapeutics Screening Assay: a high-throughput drug-discovery platform utilizing neurons and microglia derived from human induced pluripotent stem cells and Kinetic Image Cytometry$301K
- Federal grantHealth and Human S · Phase I · The Stem Cell-Derived Muscle Function Assay: A High Throughput Screening Platform Utilizing Kinetic Image Cytometry to Discover Therapeutics for Duchenne Muscular Dystrophy$225K
- Federal grantHealth and Human S · Phase I · The Microscopic Imaging of Epigenetic Landscape- NeuroDevelopment (MIEL-ND) assay: a high throughput platform to screen compounds for neurodevelopmental effects$300K
- Federal grantHealth and Human S · Phase II · Assay of environmental toxicants for toxicity related to Alzheimer's Disease utilizing human iPSC-derived- neurons and microglia$514K
- Federal grantHealth and Human S · Phase II · Assay of chemicals for Parkinson's toxicity in human iPSC-derived neurons$752K
- Federal grantHealth and Human S · Phase II · Stem cell toxicology assays for cardiac differentiation$738K
- Federal grantHealth and Human S · Phase II · Stem cell toxicology assays for cardiac differentiation$762K
- Federal grantHealth and Human S · Phase I · Assay of chemicals for Parkinson’s toxicity in human iPSC-derived neurons$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Federal first
1month
from VALA SCIENCES, INC.’s first federal award to its first private round.
- First federal award · Aug 2015
- Health and Human S · $225K
- First Form D · Sep 2015
- $1.3M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 112 peers
Line = medianMedtech · Instrument
- Federal grants#6 · top 5%
- Granted patents#18 · top 16%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jeffrey PriceResearcherExecutive Officer, DirectorLinked by $5.6M in grants as PI
- David U'PrichardDirectorNamed in SEC Form D filings
- John WestwickDirectorNamed in SEC Form D filings
- Mark McWilliamsDirectorNamed in SEC Form D filings
- Michael GeremiaExecutive OfficerNamed in SEC Form D filings
- Terry MeadorExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 13- PendingMODIFIED INDUCED PLURIPOTENT STEM CELL (iPSC) DERIVED MICROGLIA FOR THE TREATMENT OF BRAIN CANCERUSPTOApplication 17720753
- GrantedAnalysis Of Action Potentials, Transients, And Ion Flux In Excitable CellsUSPTOUS 10,928,308
- GrantedAnalysis Of Action Potentials, Transients, And Ion Flux In Excitable CellsUSPTOUS 10,359,357
Show all 13 patent records
- MODIFIED INDUCED PLURIPOTENT STEM CELL (iPSC) DERIVED MICROGLIA FOR THE TREATMENT OF BRAIN CANCERNov 3, 2022 · Application 17720753Pending
- Analysis Of Action Potentials, Transients, And Ion Flux In Excitable CellsFeb 23, 2021 · US 10,928,308Granted
- Analysis Of Action Potentials, Transients, And Ion Flux In Excitable CellsJul 23, 2019 · US 10,359,357Granted
- Calibration Standards For Digital HistocytometryApr 12, 2018 · Application 15840666Pending
- Analysis of Action Potentials, Transients, and Ion Flux in Excitable CellsApr 10, 2018 · US 9,939,372Granted
- Continuous-Scanning Image Acquisition In Automated Microscopy Using Reflective AutofocusNov 2, 2017 · Application 15653920Pending
- Continuous-Scanning Image Acquisition in Automated Microscopy Using Reflective AutofocusJun 19, 2014 · Application 13714292Pending
- Calibration Standards For Digital HistocytometryDec 19, 2013 · Application 13857954Pending
- Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern AnalysisDec 19, 2013 · Application 13865121Pending
- Analysis Of Action Potentials, Transients, And Ion Flux In Excitable CellsApplication PCTUS2013075488Pending
- Analysis of Action Potentials, Transients, and Ion Flux in Excitable CellsApplication 61737663Pending
- MODIFIED INDUCED PLURIPOTENT STEM CELL (iPSC) DERIVED MICROGLIA FOR THE TREATMENT OF BRAIN CANCERApplication 63181600Pending
- System, Method And Kit For Processing A Magnified Image Of Biological Material To Identify Components Of A Biological ObjectApplication PCTUS2006044936Pending
Related companies, and why
- PEROSPHERE TECHNOLOGIES INC.Similar federal contract value in Medtech · null in contracts
- CoachSafe PlaySafe LLCSimilar federal contract value in Medtech · null in contracts
- MOONLIGHT THERAPEUTICS, INC.Similar federal contract value in Medtech · null in contracts
- OPTOFLUIDICS, INC.Similar federal contract value in Medtech · null in contracts
- MaGPaD, LLCSimilar federal contract value in Medtech · null in contracts
- AI OPTICS INC.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .